A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Arthritis is an inflammation of one or more joints that is characterized by pain, stiffness (especially in the early morning or after exercise), swelling, deformation, and/or reduced mobility. Osteoarthritis, also known as degenerative arthritis, is caused by abnormal damage to the cartilage at the ends of bones. Some patients are caused by injury or congenital abnormalities in the proteins that make up cartilage.
Once the cartilage tissue changes from smooth to rough, or into small pieces. Cartilage is gradually destroyed, and the normally smooth surface becomes irregular. Osteoarthritis usually occurs in joints that require weight load, such as the spine, knees, hips and back, and is usually preceded by some pain and Symptoms of stiffness (mostly stiffness first, then pain), but swelling is not necessarily present. However, a small number of them will cause disability, but once the bones become more fragmented, they are more likely to cause fractures. When osteoarthritis is more severe, the bones can overgrow into osteophytes, known as bone spurs. When bone spurs develop, they can be detected with X-rays, usually in the neck or waist near degenerative cartilage. Formation, these phenomena will not produce any changes in appearance.
Osteoarthritis usually does not occur in adults under the age of 40. Most patients are over the age of 60. Symptoms may be so mild that you are unaware of them until detected by X-ray. The incidence is almost higher in women than in men. three times. Degenerative arthritis is increasing among the elderly in Taiwan. It has become a very important health problem and directly affects the quality of life. Pain control can improve the quality of life.
Previous studies have shown that orally administered hyaluronic acid (HA) can bind to toll-like receptor 4 (TLR-4) on intestinal epithelial cells, thereby increasing the secretion of the anti-inflammatory cytokine IL-10 and suppressor of cytokine signaling 3 (SOCS3), while suppressing the expression of the pro-inflammatory cytokine pleiotrophin, ultimately alleviating osteoarthritis. Regarding the regulation of cartilage degradation-related factors, HA can reduce irregularities on the cartilage surface as well as the loss of cartilage tissue and chondrocytes by suppressing the mRNA expression of MMP-3, MMP-9, and MMP-13 in cartilage tissue. In terms of oxidative stress, HA may also alleviate cartilage damage by downregulating inducible nitric oxide synthase (iNOS), thereby reducing nitric oxide (NO) production, and by inhibiting cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) production. To further enhance its efficacy in improving osteoarthritis, hyaluronic acid was combined with glucosamine and chondroitin. Previous studies have demonstrated that these two ingredients can improve connective tissue function and reduce cartilage matrix degradation. Therefore, the aim of this study was to investigate the effects of A+HA premium oral hyaluronic acid drink on improving knee pain.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Taipei, 대만
- Taipei Medical University
-
연락하다:
- YiWen Chien, PhD
- 전화번호: +886 2-27361661 #28363
- 이메일: ychien@tmu.edu.tw
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Aged 45 to 80 years.
- Knee osteoarthritis classified as Ahlbäck stage I or II, or Kellgren-Lawrence grade <3.
- A Visual Analogue Scale (VAS) pain score ≤3.
- A Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score >2 or a total WOMAC score >12.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Individuals with a history of knee joint trauma or surgery.
- A body mass index (BMI) ≥ 40 kg/m².
- Individuals with a psychiatric disorder.
- Individuals with severe cardiovascular disease, severe cerebrovascular disease, severe rheumatic disease, crystal deposition arthropathy, or cancer.
- Individuals who use a wheelchair and have a Manual Muscle Testing (MMT) grade ≤3 in the lower extremities, or who require a wheelchair due to physical discomfort.
- Use of anti-inflammatory analgesics, corticosteroids, or other medications that may affect the study outcomes within one week before the trial.
- Receipt of intra-articular corticosteroid injections, hyaluronic acid injections, platelet-rich plasma (PRP) therapy, or nerve block treatment within one month before the trial.
- Use of medications or consumption of foods that, in the judgment of a physician or dietitian, may affect the outcome measures.
- Any other condition considered by the physician to make the individual unsuitable for participation in the trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Placebo use contents without active ingredients
|
1 drink daily
|
|
실험적: A+HA premium oral hyaluronic acid drink
A+HA premium oral hyaluronic acid drink contains hyaluronic acid, glucosamine hydrochloride, and chondroitin
|
1 drink daily
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Points change of pain evaluation scale
기간: From the start to the end of treatment at 12 weeks
|
Self-assess pain using a visual analog scale (VAS), which is a straight line 10 cm in length, with 0 cm on the left representing no pain and 10 cm on the right representing extreme pain.
Explain to the subjects that the pain intensity increases from left to right.
Ask the subjects to mark the point on the line that corresponds to their pain level, and then record the distance in centimeters from the 0 cm mark.
Record the points that the subjects wrote.
|
From the start to the end of treatment at 12 weeks
|
|
Points change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
기간: From the start to the end of treatment at 12 weeks
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a widely used questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, and the total score was 96 points (Minimum: 0 points; Maximum: 96 points).
The question content was divided into three parts: Pain (20 points), Stiffness (8 points), and Physical function (68 points).
The higher score meant worse knee joint function.
Record the points that the subjects got.
|
From the start to the end of treatment at 12 weeks
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Concentration change of aspartate aminotransferase (AST)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of alanine aminotransferase (ALT)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of blood glucose
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of high-density lipoprotein
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of low-density lipoprotein
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of free fatty acid
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of cholesterol
기간: From the start to the end of the treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of the treatment at 12 weeks
|
|
Concentration change of triglyceride
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Count change of differential count (DC)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Mean corpuscular volume (MCV)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of hemoglobin
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of hematocrit
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Red blood cell count
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of gamma-glutamyl transferase (γ-GT)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of albumin
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of blood urea nitrogen (BUN)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of creatinine
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urea acid
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of thyroid-stimulating hormone (TSH)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of triiodothyronine (T3)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of thyroxine (T4)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of sodium (Na)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of potassium (K)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of calcium (Ca)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of magnesium (Mg)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of phosphorus (P)
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Change of urine pH value
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urine protein
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urine glucose
기간: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
공동 작업자 및 조사자
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- N202606002
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .